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Abstract
Obesity, type 2 diabetes and hyperlipidemia frequently coexist and are associated with significantly increased
morbidity and mortality. Consumption of refined carbohydrate and particularly fructose has increased significantly
in recent years and has paralled the increased incidence of obesity and diabetes. Human and animal studies have
demonstrated that high dietary fructose intake positively correlates with increased dyslipidemia, insulin resistance,
and hypertension. Metabolism of fructose occurs primarily in the liver and high fructose flux leads to enhanced
hepatic triglyceride accumulation (hepatic steatosis). This results in impaired glucose and lipid metabolism and
increased proinflammatory cytokine expression. Here we demonstrate that fructose alters glucose-stimulated
expression of activated acetyl CoA carboxylase (ACC), pSer hormone sensitive lipase (pSerHSL) and adipose
triglyceride lipase (ATGL) in hepatic HepG2 or primary hepatic cell cultures in vitro. This was associated with
increased de novo triglyceride synthesis in vitro and hepatic steatosis in vivo in fructose- versus glucose-fed and
standard-diet fed mice. These studies provide novel insight into the mechanisms involved in fructose-mediated
hepatic hypertriglyceridemia and identify fructose-uptake as a new potential therapeutic target for lipid-associated
diseases.
Introduction
Obesity, type 2 diabetes and hyperlipidemia frequently
coexist and are associated with significantly increased
morbidity and mortality [1]. A significant increase in
total refined carbohydrate intake and particularly fruc-
tose has paralled recent increased incidence of obesity
and diabetes. Metabolism of sugars and particularly
fructose occurs primarily in the liver and high fructose
flux leads to enhanced hepatic triglyceride accumulation
resulting in impaired glucose and lipid metabolism and
increased proinflammatory cytokine expression [2-6].
The role that triglycerides play as an independent risk
factor for CAD is still not well defined but a substantial
number of individuals who maintain total plasma choles-
terol concentrations within acceptable values (< 5.17
mmol/L or 200 mg/dL) still develop CAD [7,8]. Some of
these patients have low HDL -cholesterol concentrations
(< 0.91 mmol/L or 35 mg/dL) [9,10] and a decline in
HDL-cholesterol often accompanies an increase in VLDL
triglyceride, reflecting an interchange of cholesterol
esters from HDL for triglyceride from VLDL [11-16]. In
addition to lipid abnormalities, hyperinsulinemia also
plays an important role in CAD risk and triglyceride con-
centrations are highly correlated to plasma insulin
response to carbohydrate [17-22].
Given that dietary fructose has been associated with
hypertriglyceridemia and insulin resistance, primarily of
hepatic origin, the aim of this study was to evaluate the
effects of fructose on hepatic intracellular triglyceride
metabolism and gain some insight into the mechanisms by
which fructose enhances hepatic lipogenesis. Here we
demonstrate that addition of fructose to human hepatic
HepG2 cells and primary murine hepatic cell cultures
incubated in physiologic and diabetic-range glucose con-
centrations in vitro disrupts normal glucose metabolism
and leads to hepatic triglyceride accumulation in associa-
tion with reduced hepatic expression of phosphorylated
acetyl CoA carboxylase (pSer
479 ACC), phopshorylated
hormone sensitive lipase (pSer
660 HSL) and total adipose
triglyceride lipase (ATGL) in comparison to glucose alone.
Additionally fructose-fed athymic Nu/Nu mice exhibited
increased hepatic steatosis in association with reduced
hepatic ATGL expression in comparison to glucose- and
standard defined diet-fed mice.
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Cell culture and hepatocyte isolation
Human hepatoma HepG2 cells purchased from ATCC
w e r eg r o w na t3 7 ° Ci n5 %C O 2 in DMEM medium with
10% FBS, 500 mM Hepes, glutamine, penicillin (100 U/ml)
and streptomycin (100 ug/ml) (Invitrogen). Hepatic tissue
was harvested from 3-mth old male C57/Bl6 mice and pri-
mary hepatic cell culture performed as previously reported
[23]. At 30% confluence, HepG2 or primary hepatocyte
cells were treated with glucose free DMEM with 5% FBS
overnight and then incubated with glucose ( 5.5 and
11.1 mM) or fructose ( 0.55 mM) concentrations alone or
fructose (0.55 mM) in combination with physiological glu-
cose (5.5 mM) or high glucose (11.1 mM) for 72 hours.
Tissue culture materials and other reagents were obtained
from Sigma Chemical Co. (St. Louis, MO).
Metabolomic Studies
75% confluent cultures of HepG2 cells (3 × 10
6)w e r e
incubated for 72 h in 5.5 mM glucose, 11.1 mM glucose
alone or 5.5 mM glucose in combination with 5.5 mM
fructose, all of which contained a 10% solution of
13C
tracer - [1,2-
13C2] D-glucose (> 99% purity, and 99% iso-
tope enrichment for each carbon position) (Cambridge
Isotope Labs, Massachusetts) in T75 culture flasks. Fol-
lowing the glucose- or combination glucose/fructose
treatment, culture medium was collected and cells were
washed twice in PBS. Cell pellets were then harvested
and palmitate, and oleate were extracted after saponifi-
cation of cell pellets in 30% KOH and 100% ethanol
using petroleum ether. Fatty acids were then converted
to their methylated derivative using 0.5N methanolic-
HCL and mass spectral data then obtained on a HP5973
mass selective detector connected to an HP6890 gas
chromatograph. Palmitate and oleate were monitored at
m/z 270 and m/z 264, respectively, with the enrichment
of
13C labeled acetyl units to reflect synthesis, elongation
and desaturation of the new lipid fraction as determined
by mass isotopomer distribution analysis (MIDA) [24].
Western blotting
Cell lysates or homogenized frozen hepatic tissue (100-120
mg) were solubilized in buffer. Lysates were cleared by
centrifugation and total protein concentration determined
using a BioRad DC kit. 30 ug of the proteins were sepa-
rated by 10% SDS-PAGE and transferred to nitrocellulose
membranes, followed by immunoblotting using specific
primary and secondary antibodies and visualized using
SuperSignal Chemiluminescence Assay kit (Pierce Inc.,
Rockville, MD). Antibodies to pSer
79 ACC, total ACC,
pSer
660 HSL, total HSL and ATGL were from Cell Signal-
ing Technology (Danvers, MA) and b-actin was from
Santa Cruz Biotechnology (Santa Cruz, CA).
Animals and Diet
All procedures were approved by the UCLA Animal
Research Committee. Three-month old male athymic
Nu/Nu mice purchased from Jackson Labs were housed
individually in open-topped cages undera 12-hour light
and 12-hour dark regimen and groups of six mice fed
isocaloric (3675 kcal./kg) defined diets; standard (STD)
diet (10% sucrose, 47% cornstarch), high glucose (HG,
60% glucose) or high fructose (HF, 60% fructose) diets
[Dyets Inc, Pennsylvania, USA] for 12 weeks. Food
intake and body weights were determined weekly. For
intraperitoneal glucose tolerance tests (IPGT), mice
were fasted overnight and retro-orbital blood glucose
monitored at baseline (0), 15, 30, 60 and 120 minutes
using a glucometer (Lifescan) after intraperitoneal glu-
cose loading (1 g glucose per kg body weight) and area
under the curve (AOC, mg/dl × min) for glucose levels
during IPGT’s was calculated for each group as pre-
viously described. All assays were carried out in tripli-
cate and expressed asmean ± SEM. Insulin was
measured in plasma samples by RIA (Linco, St. Charles,
Missouri). Histological analysis was performed on paraf-
fin-embedded hepatic tissues using consecutive 5-μm
sections stained with hematoxylin and eosin. Briefly,
1/3 of the left posterior lobe of the liver was fixed in
10% neutral-buffered formalin for 24h, processed though
graded alcohols and xylene and embedded in paraffin.
5-μm sections were deparaffinized and stained with
hematoxylin and eosin (HE) using routine methods. Fat
deposition was also analyzed in 8-μmf r o z e nl i v e rs e c -
tions stained with 0.18% oil red O (Sigma-Aldrich) with
60% 2-propanol (Sigma-Aldrich) for 20 minutes at 37°
and counterstained with hematoxylin. Fat accumulation
stained with oil red O was quantified using an Image-
Pro Plus Analyzer (Media Cybernetics, Inc., Bethesda,
M D )b yap a t h o l o g i s t( W .Y o n g ) .T oq u a n t i f yh e p a t i c
triglyceride content, liver tissues (100 mg) were homo-
g e n i z e di ni c e - c o l d2 0m m o l / LT r i s - H C l ,1 5 0m m o l / L
NaCl, 2 mmol/L EDTA, and 1% Triton X-100, pH 7.5,
triglycerides extracted with chloroform/methanol (2:1)
and triglycerides quantitated using a commercially
available kit (Infinity Triglycerides Stable Reagent,
Thermo Electron) and correlated to total hepatic protein
content. Oil Red O-staining was used to measure cellu-
lar neutral lipid droplet accumulation in vitro in the
HepG2cells [25].
Statistical analysis
Results are expressed as mean ± SEM (metabolomic
experiments mean +/- SD) and analysis performed by
ANOVA with Bonferroni comparison tests or nonpara-
metric t- test (one tailed/unpaired) as indicated.
P values < 0.05 were considered significant.
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Fructose increases in vitro hepatic triglyceride storage
and secretion
Following growth of HepG2 cells for 72 h in medium
containing either 5.5 mM or 11.1 mM glucose alone or
5.5 mM glucose in combination with 5.5 mM fructose,
all of which contained a 10% solution of
13Ct r a c e r-
[1,2-
13C2] D-glucose, we analyzed cell media and pellets
by GC-mass spectroscopy to quantitate intra- and extra-
cellular plamitate and oleate levels to examine the effects
of fructose on hepatic triglyceride metabolism in vitro.
As depicted in figure 1, extracellular palmitate levels
were 2-fold higher when fructose was added to HepG2
cells incubated in physiologica n dd i a b e t i cr a n g eg l u c o s e
concentrations compared to glucose alone (figure 1a)
(Mean ± SD extracellular palmitate: G 5.5 mM 23 ± 3;
G 11.1 mM, 20 ± 0.8, G 5.5 mM & F 5.5 mM, 46 ± 5.8,
p < 0.01). We also observed a 4-fold increase in extracel-
lular oleate concentrations in the fructose-treated cells in
keeping with increased hepatic cell secretion of these
newly synthesized fatty acids. (figure 1b) (Mean ± SD
extracellular oleate: G 5.5 mM, 10 ± 3; G 11.1 mM, 9.5 ±
0.8; G 5.5 mM & F 5.5 mM, 39 ± 7, p < 0.01). Oil-red-O
staining (figure 1c & d) was increased in the hepatocytes
co-treated with 11 mM glucose plus 0.55 mM fructose in
comparison to 11.1 mM glucose-treatment alone (** p <
0.01) reflecting higher triglyceride content. To assess the
contribution of the sugars to de novo fatty acid synthesis,
we also examined tracer substrate-derived acetyl-CoA
enrichment in cell palmitate. Acetyl-CoA contribution to
new palmitate synthesis from glucose (figure 1e) was
relatively low at 1.88% and was further decreased by fruc-
tose-treatment, likely due to the direct contribution of
fructose derived acetyl-CoA to palmitate synthesis.
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Figure 1 Fructose increases glucose-stimulated triglyceride synthesis. Metabolomic studies in HepG2 cells treated with either glucose (5.5
or 11 mM) alone or or admixed glucose (5.5 or 11.1 mM) and fructose (5.5 mM) concentrations depicting enrichment of
13C labeled acetyl units
reflecting synthesis, elongation and desaturation of new lipid fractions as determined by mass isotopomer distribution analysis (MIDA) (a)
extracellular palmitate and (b) oleate. Photomicrographs (c) and quantitation (d) of of oil-red-O staining in human HepG2 cells following
incubation (72h) in fructose (0.55 mM) and glucose (5.5 & 11.1 mM) alone or admixed glucose (5.5 or 11.1 mM) and fructose (0.55 mM)
concentrations. (e) Relative Acetyl CoA enrichment from the [1,2-
13C2] D-glucose. G; glucose; F, fructose. *, p < 0.05; ** p < 0.01.
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synthesis and hydrolysis
As our metabolomic studies had demonstrated increased
de novo triglyceride synthesis and secretion in hepatic
cells cultured in 11 mM glucose co-treated with low
concentration fructose, we next sought to explore the
mechanism(s) by which fructose resulted in increased
hepatic triglycerides. Hepatic triglyceride synthesis
involves multiple metabolic pathways, including glycoly-
sis and pyruvate oxidation which generate acetyl-CoA.
Acetyl CoA is then converted to malonyl-CoA by the
enzyme acetyl CoA carboxylase before conversion to
palmitate by fatty acid synthase [26].
Therefore, we first compared effects of glucose-
(5.5 and 11.1 mM) or fructose- (0.55 mM) treatment
alone in vitro on several key enzymes involved in hepatic
triglyceride synthesis and hydrolysis in human hepatic
HepG2 cells and primary murine hepatic cell cultures. As
depicted in figure 2a-b, in vitro glucose-treatment (5.5 &
11.1 mM) increased serine-phosphorylated acetyl Co-
carboxylase (pSer
79 ACC) levels, in keeping with
increased de novo fatty acid synthesis. In contrast, follow-
ing fructose-treatment alone (0.55 mM) although total
ACC levels fell, corrected pSer
79 ACC expression was
similar to that observed in glucose-treated cells. How-
ever, when fructose (0.55 mM) was added to either 5.5 or
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Figure 2 Fructose impairs glucose-induced hepatic triglyceride synthesis and hydrolysis. Immunoblots and quantitation depicting (a & b)
pSer
79 Acetyl CoA Carboxylase (ACC), total ACC and (c & d) pSer
660 hormone sensitive lipase (HSL), total HSL and (c & e) total adipose
triglyceride lipase (ATGL) in human HepG2 cells following incubation (72h) in glucose (5.5 & 11.1 mM) or fructose (0.55 mM) alone or an
admixture of glucose (5.5 & 11.1 mM) together with 0.55 mM fructose concentrations. b-actin served as a loading control. G; glucose; F,
fructose. * p < 0.05, ** p < 0.01.
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Page 4 of 1011.1 mM glucose, pSer
79 ACC levels were lower in
comparison to levels observed in glucose-treated cells (*
p < 0.05, ** p < 0.01). We also compared expression of
activated serine-phosphorylated hormone sensitive lipase
(pSer
660 HSL) and adipose triglyceride lipase (ATGL)
expression in the HepG2 cells. As demonstrated in
figure 2c-e, pSer
660 HSL expression also increased in
HepG2 cells treated with glucose (p = ns) but was sig-
nificantly lower in cells treated with fructose only (* p <
0.05) and combination fructose- and glucose-treatment
resulted in lower pSer
660 HSL expression compared to
glucose alone (*, p < 0.01). ATGL expression was higher
in glucose versus fructose-treated cells and combination
treatment led to reduced ATGL expression (figure 2e)
(* p < 0.05).
Fructose impairs murine hepatic triglyceride synthesis
in vitro
We also tested the effects of combination fructose- and
glucose-treatment in primary murine hepatocytes. As
depicted in figure 3a & b, addition of 5.5 mM glucose or
fructose alone to primary murine hepatocytes resulted in
similar corrected pSer
79 ACC levels. In contrast, addition
of fructose to the primary hepatocytes treated with
5.5 mM glucose led to a 1.5-fold reduction in pSer
79
ACC in comparison to 5.5 mM glucose-treatment alone
(*, p < 0.05). The effect of co-treatment with fructose
(0.55 mM) and 11.1 mM glucose was even more striking
and resulted in virtual abrogation of pSer
79 ACC in the
primary hepatocytes with a ~5-fold reduction in pSer
79
ACC levels in comparison to 11.1 mM glucose-treatment
c.
2
6
10
p
S
e
r
6
6
0
H
S
L
 
t
o
T
o
t
a
l
 
H
S
L
 
r
a
t
i
o d.
*
a. ACC pSer79
ACC
E-actin
2
6
10 **
p
S
e
r
7
9
A
C
C
 
t
o
T
o
t
a
l
 
A
C
C
 
r
a
t
i
o b.
F 0.55 G 5.5 +
F 0.55
G 11.1 mM +
F 0.55 mM
G 11.1 G 5.5
2
6
10
T
o
t
a
l
 
A
T
G
L
 
t
o
A
c
t
i
n
r
a
t
i
o
e.
F 0.55 G 5.5 +
F 0.55
G 11.1 mM +
F 0.55 mM
G 11.1 G 5.5
**
**
ATGL
E-actin
pSer660HSL
HSL
Figure 3 Fructose impairs ACC phosphorylation in primary murine hepatocytes. Immunoblots and quantitation depicting (a & b) pSer
79
Acetyl CoA Carboxylase (ACC) and total ACC and (c & d) pSer
660 hormone sensitive lipase (HSL), total HSL and (c & e) total adipose triglyceride
lipase (ATGL) in primary cultures of murine hepatocytes following incubation (72h) in glucose (5.5 & 11.1 mM) or fructose (0.55 mM) alone or an
admixture of glucose (0.055 & 11.1 mM) together with 0.55 mM fructose concentrations. b-actin served as a loading control. G; glucose; F,
fructose. * p < 0.05, ** p < 0.01.
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Page 5 of 10alone (** p < 0.01). As demonstrated in figure 3c-e,
co-treatment with fructose and glucose alone suppressed
11 mM glucose-stimulated p
Ser 660HSL (p < 0.01) and
ATGL levels (p < 0.01) in the primary murine hepato-
cytes in comparison to 11.1 mM glucose-treatment alone.
Dietary fructose impairs glucose disposal and glucose-
stimulated insulin release
In light of our in vitro findings, we next examined
effects of dietary fructose versus glucose on hepatic tri-
glyceriude synthesis in vivo. Although fructose-feeding
has been shown to induce impaired insulin action and
increased hepatic steatosis in several rodent species
including rats and hamsters, C57Bl/6 mice appear com-
paratively resistant to carbohydrate-induced effects.
Therefore, we fed athymic Nu/Nu mice either isocaloric
defined diets, so-called standard (STD-), 60% glucose
(HG-) or 60% fructose (HF-) diets for 12 weeks and
then measured glucose and insulin levels across a stan-
dard intraperitoneal glucose tolerance test (1 gm/kg glu-
cose). As depicted in figure 4a-d, glucose disposal as
measured by calculating the area under the glucose
curve, was similar in mice fed either the HG- and STD-
diets but reduced in the fructose fed animals (*, p < 0.05
STD or HG vs HF). In STD-diet fed mice, insulin levels
rose ~2.6-fold from baseline following the glucose load,
p < 0.002 (figure 4e), whereas mice fed the HG- diet
demonstrated a reduced ~1.6-fold increase in insulin
levels. Fructose-fed mice exhibited an even lower
1.3-fold glucose-stimulated increase in insulin (fructose
versus glucose, p < 0.05). The results demonstrate that
both high glucose- and high fructose-feeding resulted in
reduced glucose-stimulated insulin release in compari-
son to standard diet in the athymic Nu/Nu mouse
model and that fructose-fed mice also exhibited
impaired glucose disposal.
Refined carbohydrate induces hepatic steatosis and
elevated hepatic triglyceride levels in vivo
Food-intake and final body weights did not differ
amongst the STD-, HG-, or HF- diet fed mice. Liver
weights were higher in mice fed the HF-diet in compari-
son to the HG- and STD-diet fed mice (mean ± SEM
hepatic Wt: STD; 0.9 ± 0.01; HG, 1.2 ± 0.01; HF 1.6 ±
0.01 g, p < 0.05 ). Hepatic histology demonstrated mark-
edly increased micro and macro steatosis in fructose-fed
mice which was 2.7-fold higher compared to HG-fed
animals (p < 0.05) and 4.5-fold higher than steatosis
observed in STD-diet fed mice (p < 0.01) (Ffigure 5a &
b). Hepatic triglyceride levels were 1.3-fold higher in
liver tissues from HG-fed mice in comparison to STD-
fed animals but the highest hepatic Tg levels were seen
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Figure 4 Effect of dietary fructose on glucose disposal. (a) Intraperitoneal glucose tolerance tests in mice following 12-week standard (STD)
(hatched line) high glucose (HG) (solid line) or high fructose (HF) (dotted line) diets depicting glucose levels after overnight fast at baseline (0), 15,
30, 60 and 120 minutes after glucose 1 g/kg administration. The area under the curve (AOC) (Mean SD) for each of the groups is depicted in the
bar chart (d). (e) Insulin levels at baseline and following the IP glucose load in the three groups. STD, standard diet; HG, high glucose diet; HF,
high fructose diet. *, p < 0.05, **, p < 0.01.
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were 1.7-fold higher than STD-fed (p < 0.01), and 1.3-
fold higher than HG-fed mice (p < 0.05) (figure 5c),
illustrating the potent effect of dietary fructose on hepa-
tic triglyceride levels. Given our in vitro findings, we
also examined expression of the hepatic triglyceride
enzymes (pSer
79 ACC, total ACC, pSer
660 HSL, total
HSL and ATGL) in a randomly selected subset of
12 mice fed the STD-, 60% glucose or 60%-fructose-
containing diets. No significant alterations in in vivo
pSer
660 HSL or pSer
79 ACC expression (not shown)
were observed but as demonstrated in figure 5c & d,
lower ATGL levels were observed in fructose-fed mice
in comparison to glucose- (p < 0.05) or standard-diet
animals (p < 0.01).
Discussion
Several human and animal studies have demonstrated
that dietary fructose intake increases triglyceride levels
[27-34]. In humans, these lipid alterations occur quite
quickly as evidenced by a 10 week study in 32 men &
women who ate a 15% protein, 30% fat and 55% carbo-
hydrate diet where 25% of calories were replaced with a
glucose- or fructose-containing drink. De novo hepatic
lipogenesis, markers of altered lipid metabolism and
lipoprotein remodeling, including fasting apoB, LDL,
small dense LDL and oxidized LDL all increased [32].
The postprandial triglyceride response in particular
increased 10% in the fructose-treated group in compari-
son to glucose, emphasizing the role of the hepatic
response to fructose loads [32]. However, the molecular
mechanisms by which high fructose diets induce
abnormalities in liver triglyceride metabolism are not
fully understood [35-37].
Synthesis of hepatic TGs involves multiple metabolic
pathways, including glycolysis and pyruvate oxidation to
generate acetyl-CoA. Our
13C glucose tracer studies
demonstrate increased intracellular palmitate and extra-
cellular oleate concentration in fructose and glucose-
cotreated cells compared to glucose-treated cells in
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Figure 5 Fructose increases hepatic steatosis and triglyceride content. (a) Photomicrographs depicting hematoxylin & eosin staining of
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Page 7 of 10keeping with increased “de novo” fatty acid synthesis
[26]. Our molecular in vitro studies demonstrate that
addition of fructose to glucose-treated hepatic cells
leads to reduced serine-phosphorylated ACC, HSL and
A T G L[ 3 8 ] .T h e r e f o r e ,i na d d i t i o nt os e r v i n ga sas u b -
strate for enhanced de-novo fatty acid synthesis, fructose
and or its intermediate metabolites may also alter
expression of several enzymes involved in hepatic lipid
synthesis and hydrolysis pathways.
As we observed increased extracellular oleate concen-
trations in the fructose-treated liver cells, this study
indicates that in addition to increasing de novo hepatic
fatty acid synthesis, fructose-treatment also leads to
enhanced triglyceride secretion, as when triglycerides
are assembled for release, they require oleate to provide
fluidity. The combination of increased fatty acid synth-
esis and triglyceride release provides novel insight into
the hepatic steatosis that has been demonstrated in ani-
mal models following dietary fructose and in humans
where fructose intake correlates with prevalence of fatty
liver [27,28,34,39].
Our studies have focused on the liver as approxi-
mately 40% of ingested fructose is extracted and meta-
bolized in the liver. Adipose tissue serves as the main
TG store but they are also stored in non-adipose tissues
including muscle and liver where they can provide fatty
acid substrate for metabolic processes [40]. Additionally,
studies have shown that fructose plays a specific role in
the pathogenesis of hepatic steatosis and metabolic syn-
drome due to differential hepatic fructose metabolism.
Unlike most tissues which contain only hexokinase that
competitively phosphorylates glucose or fructose at the
sixth carbon [41], hepatocytes also express fructokinase-
1 that phosphorylates fructose on
1C to generate fruc-
tose 1- phosphate. Fructose-1-phosphate can then be
metabolized into dihydroxyacetone phosphate and gly-
ceraldehydes entering the latter steps of the Embden-
Meyerhof pathway to generate triacylglycerol. As this
entry point is distal to the glycolysis rate limiting
enzyme phospho fructokinase-1, unlike glucose, fructose
can serve as a relatively unregulated source of acetyl-
CoA [4]. However, the contribution of glycolysis to de-
novo hepatic fatty acid synthesis is small (< 10%) as sup-
ported by our metabolomic studies. Therefore, other
mechanisms to increase fatty acid synthesis are likely
more important including, fructose 1, 6 bis-phosphate
which is a potent regulator of fatty acid synthesis by
directly activating fatty acid synthase.
Although dietary carbohydrate induces insulin resis-
tance in rats and hamsters, most commonly employed
mice strains such as C57Bl/6 appear to be relatively
resistant to CHO-induced metabolic syndrome [42]. The
athymic Nu/Nu mouse represents a model of non obese
non-immune non-insulin-dependent diabetes [43,44]
and has been used to delineate immune-mediated pan-
creatic islet effects in insulin-dependent diabetes melli-
tus [45,46]. Our studies demonstrate that unlike the
C57Bl/6 mouse, increased CHO feeding to Nu/Nu mice
results in development of a metabolic syndrome pheno-
type with modestly impaired peripheral glucose disposal.
In contrast to our in vitro finding of reduced pS79ACC
levels following fructose, we did not see changes in in
vivo hepatic pS79ACC, ACC and/or pSer
660 HSL or
total HSL expression [39]. This is unusual, given that
ACC is the rate-limiting enzyme in lipogenesis but may
be due to other actions of the sugars to alter ACC
aggregation or other longer chain CoA. Given that glu-
cose-stimulated insulin levels were attenuated in the
fructose-fed mice in comparison to glucose- and stan-
dard-diet fed mice, our studies also suggest that fruc-
tose-fed mice may exhibit a degree of beta-cell
impairment and this is an area that we are currently
investigating.
It is important to acknowledge that our animal in vivo
studies employed higher refined carbohydrate content
(60% of energy) than would be consumed in a typical
western diet (7.5-20% of energy) and the relevance of in
vivo findings in these stylized animal models to humans
can reasonably be questioned. However, our in vitro
study fructose concentrations (0.5 mM) are easily attain-
able in the peripheral human circulation and fructose
concentrations can be predicted to be higher in post-
prandial portal venous blood in subjects consuming
average Western diets containing 10-15% refined carbo-
hydrate [32].
It is widely appreciated that increases in triglycerides
are typically more pronounced in obese patients with
insulin resistance. Our studies demonstrating that the
fructose effect to interfere with hepatic lipid metabolism
is more marked in hyperglycemic conditions is of
importance to diabetic patients as they suggest that
fructose consumption may exacerbate an already exist-
ing adverse metabolic profile especially in diabetic
patients who have poor glycemic control. However, the
adverse effects of fructose on hepatic lipid metabolism
are not restricted to poorly controlled diabetic patients
as our in vitro experiments demonstrate that even low
concentrations of fructose can disrupt normal hepatic
glucose metabolism.
In summary, our studies provide novel insight into the
mechanism of fructose-induced hepatic hypertriglyceri-
demia and show that fructose, a component of sucrose
(table sugar) and high fructose corn syrup, leads to
increased de novo hepatic fatty acid synthesis and
release of triglycerides in comparison to glucose. This
not only entails differential utilization of fructose as a
substrate for de novo fatty acid synthesis but may also
involve alterations in the levels of key enzymes involved
Huang et al. Lipids in Health and Disease 2011, 10:20
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Page 8 of 10with fatty acid synthesis and hydrolysis including ACC-,
ATGL- and HSL. Furthermore, they support the conten-
tion that fructose-containing foods can have detrimental
effects on hepatic lipid synthesis with potentially adverse
consequences on cardiovascular risk. They have impor-
tant clinical implications given the increase in obesity
rates and its associated complications, including
diabetes.
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